Keyword: Apple Tree Partners
Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.
Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.
Akero Therapeutics raised $65 million to advance its lead program, a FGF21 analog, for the treatment of NASH.
The series A positions a team with résumés dotted with senior posts at Serono, Eli Lilly and Novartis to advance multifunctional anticancer drugs.
The document details planned investments from drug developers including GlaxoSmithKline, although many of the commitments are vague or already known.